Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

Abstract Background Studies suggest that immune checkpoint inhibitors may represent a promising strategy for boosting immune responses and improving the antitumor activity of standard therapies in patients with relapsed/refractory hematologic malignancies. Aims Phase 1/2 FUSION NHL 001 was designed...

Full description

Bibliographic Details
Main Authors: Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz, Steven Le Gouill, Koji Izutsu, Simon Rule, Pieternella Lugtenburg, Jia Ruan, Luca Arcaini, Marie‐Laure Casadebaig, Brian Fox, Nurgul Kilavuz, Nils Rettby, Justine Dell'Aringa, Lilia Taningco, Richard Delarue, Myron Czuczman, Thomas Witzig
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Cancer Reports
Subjects:
clinical trials
durvalumab
hematologic malignancies
lymphoma
programmed death ligand 1
Online Access:https://doi.org/10.1002/cnr2.1662

Internet

https://doi.org/10.1002/cnr2.1662

Similar Items